AU2013302620B2 - Stem cell enhancing therapeutics - Google Patents

Stem cell enhancing therapeutics Download PDF

Info

Publication number
AU2013302620B2
AU2013302620B2 AU2013302620A AU2013302620A AU2013302620B2 AU 2013302620 B2 AU2013302620 B2 AU 2013302620B2 AU 2013302620 A AU2013302620 A AU 2013302620A AU 2013302620 A AU2013302620 A AU 2013302620A AU 2013302620 B2 AU2013302620 B2 AU 2013302620B2
Authority
AU
Australia
Prior art keywords
ser
thr
gly
val
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013302620A
Other languages
English (en)
Other versions
AU2013302620A1 (en
Inventor
Cynthia Bamdad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Minerva Biotechnologies Corp
Original Assignee
Minerva Biotechnologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2012/060684 external-priority patent/WO2013059373A2/en
Priority claimed from PCT/US2013/025981 external-priority patent/WO2013123084A1/en
Application filed by Minerva Biotechnologies Corp filed Critical Minerva Biotechnologies Corp
Publication of AU2013302620A1 publication Critical patent/AU2013302620A1/en
Application granted granted Critical
Publication of AU2013302620B2 publication Critical patent/AU2013302620B2/en
Priority to AU2018220126A priority Critical patent/AU2018220126B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2013302620A 2012-08-14 2013-08-14 Stem cell enhancing therapeutics Active AU2013302620B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2018220126A AU2018220126B2 (en) 2012-08-14 2018-08-24 Stem cell enhancing therapeutics

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201261683155P 2012-08-14 2012-08-14
US61/683,155 2012-08-14
US201261684654P 2012-08-17 2012-08-17
US61/684,654 2012-08-17
US201261693712P 2012-08-27 2012-08-27
US61/693,712 2012-08-27
PCT/US2012/060684 WO2013059373A2 (en) 2011-10-17 2012-10-17 Media for stem cell proliferation and induction
AUPCT/US2012/060684 2012-10-17
PCT/US2013/025981 WO2013123084A1 (en) 2012-02-13 2013-02-13 Method for detecting circulating fetal cells
AUPCT/US2013/025981 2013-02-13
US201361837560P 2013-06-20 2013-06-20
US61/837,560 2013-06-20
PCT/US2013/055015 WO2014028668A2 (en) 2012-08-14 2013-08-14 Stem cell enhancing therapeutics

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018220126A Division AU2018220126B2 (en) 2012-08-14 2018-08-24 Stem cell enhancing therapeutics

Publications (2)

Publication Number Publication Date
AU2013302620A1 AU2013302620A1 (en) 2015-04-02
AU2013302620B2 true AU2013302620B2 (en) 2018-08-02

Family

ID=50101604

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2013302620A Active AU2013302620B2 (en) 2012-08-14 2013-08-14 Stem cell enhancing therapeutics
AU2018220126A Active AU2018220126B2 (en) 2012-08-14 2018-08-24 Stem cell enhancing therapeutics

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2018220126A Active AU2018220126B2 (en) 2012-08-14 2018-08-24 Stem cell enhancing therapeutics

Country Status (8)

Country Link
US (2) US9932407B2 (enExample)
EP (1) EP2885000A4 (enExample)
JP (4) JP6664219B2 (enExample)
CN (3) CN104717980A (enExample)
AU (2) AU2013302620B2 (enExample)
CA (1) CA2882222A1 (enExample)
IL (1) IL237228B (enExample)
WO (1) WO2014028668A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102239182B (zh) * 2008-10-06 2014-07-09 米纳瓦生物技术公司 Muc1*抗体
EP4050103A1 (en) 2014-04-07 2022-08-31 Minerva Biotechnologies Corporation Anti-nme antibody
JP6895890B2 (ja) * 2015-02-10 2021-06-30 ミネルバ バイオテクノロジーズ コーポレーション ヒト化抗ｍｕｃ１＊ 抗体
JP7197078B2 (ja) * 2016-04-08 2022-12-27 ジィールバイオ，インコーポレーテッド プレクチン１結合性抗体およびその使用
US20210107989A1 (en) * 2017-04-04 2021-04-15 Corvus Pharmaceuticals, Inc. Methods for treating cd73hi tumors
CN112105380A (zh) * 2017-10-11 2020-12-18 埃缇健康公司D/B/A泽尔拜尔 网蛋白-1结合抗体和其用途
CA3121624A1 (en) 2018-12-06 2020-06-11 Arthrosi Therapeutics, Inc. Methods for treating or preventing gout or hyperuricemia
CN120484122A (zh) * 2019-01-11 2025-08-15 米纳瓦生物技术公司 抗可变muc1*抗体及其用途
CN113727602B (zh) 2019-02-04 2023-10-03 米纳瓦生物技术公司 抗nme抗体及治疗癌症或癌症转移的方法
IL298780A (en) 2020-06-08 2023-02-01 Minerva Biotechnologies Corp Anti-nme antibody and method of treating cancer or cancer metastasis
CN116075318A (zh) 2020-06-26 2023-05-05 米纳瓦生物技术公司 抗nme抗体及治疗癌症或癌症转移的方法
WO2023201234A2 (en) 2022-04-12 2023-10-19 Minerva Biotechnologies Corporation Anti-variable muc1* antibodies and uses thereof
US20240261406A1 (en) 2023-02-02 2024-08-08 Minerva Biotechnologies Corporation Chimeric antigen receptor compositions and methods for treating muc1* diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008070171A2 (en) * 2006-12-06 2008-06-12 Minerva Biotechnologies Corp. Method for identifying and manipulating cells
WO2010042891A2 (en) * 2008-10-09 2010-04-15 Minerva Biotechnologies Corporation Method for inducing pluripotency in cells
US20100316688A1 (en) * 2009-06-11 2010-12-16 Bamdad Cynthia C Methods for culturing stem and progenitor cells

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0505566A1 (en) * 1989-12-15 1992-09-30 Takeda Chemical Industries, Ltd. Biospecific antibody to cancer cell and enzyme with prodrug-activating characteristics
US5342947A (en) * 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
JP2005508839A (ja) * 2001-03-29 2005-04-07 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド ペプチドおよびｍｕｃ１タンパク質に対する抗体
EP2329822A1 (en) * 2001-09-05 2011-06-08 Minerva Biotechnologies Corporation Compositions and methods of treatment of cancer
JP2006504630A (ja) * 2002-04-22 2006-02-09 ダイアックス コーポレイション ムチンポリペプチドに特異的な抗体
EP1536814A4 (en) * 2002-07-03 2006-02-15 Immunogen Inc ANTIBODIES AGAINST MUC1 AND MUC16 NOT RELEASED AND USES THEREOF
EP2526957A3 (en) 2005-03-30 2013-02-20 Minerva Biotechnologies Corporation Proliferation of MUC1 expressing cells
US7825092B2 (en) * 2006-08-08 2010-11-02 University Of South Florida Dendroaspis natriuretic peptide for treatment of cancer
US20100104626A1 (en) * 2007-02-16 2010-04-29 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
CN102239182B (zh) * 2008-10-06 2014-07-09 米纳瓦生物技术公司 Muc1*抗体
CN102264765B (zh) * 2008-10-28 2016-01-20 盐野义制药株式会社 抗muc1抗体
US8628959B2 (en) * 2009-05-23 2014-01-14 Incube Labs, Llc Methods for cancer treatment using stem cells
US20120156246A1 (en) * 2010-06-16 2012-06-21 Bamdad Cynthia C Reprogramming cancer cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008070171A2 (en) * 2006-12-06 2008-06-12 Minerva Biotechnologies Corp. Method for identifying and manipulating cells
WO2010042891A2 (en) * 2008-10-09 2010-04-15 Minerva Biotechnologies Corporation Method for inducing pluripotency in cells
US20100316688A1 (en) * 2009-06-11 2010-12-16 Bamdad Cynthia C Methods for culturing stem and progenitor cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HIKITA SHERRY T ET AL: "MUC1 mediates the growth of human pluripotent stem cells",PLOS ONE, PUBLIC LIBRARY OF SCIENCE, US, vol. 3, no. 10, 3 October 2008, page E3312 *

Also Published As

Publication number Publication date
IL237228A0 (en) 2015-04-30
CN111388664A (zh) 2020-07-10
AU2018220126A1 (en) 2018-09-13
CN104717980A (zh) 2015-06-17
US20170121406A1 (en) 2017-05-04
AU2013302620A1 (en) 2015-04-02
EP2885000A2 (en) 2015-06-24
JP2015526446A (ja) 2015-09-10
CN108175856A (zh) 2018-06-19
JP2020109101A (ja) 2020-07-16
WO2014028668A3 (en) 2014-05-01
JP2018070640A (ja) 2018-05-10
IL237228B (en) 2021-03-25
JP6757712B2 (ja) 2020-09-23
CA2882222A1 (en) 2014-02-20
EP2885000A4 (en) 2015-12-23
JP2022025136A (ja) 2022-02-09
JP6664219B2 (ja) 2020-03-13
CN108175856B (zh) 2024-01-26
US9932407B2 (en) 2018-04-03
US20150299334A1 (en) 2015-10-22
WO2014028668A2 (en) 2014-02-20
AU2018220126B2 (en) 2020-07-23

Similar Documents

Publication Publication Date Title
AU2013302620B2 (en) Stem cell enhancing therapeutics
CN107001466B (zh) 对淋巴细胞中抑制途径的中和
EP2900263B1 (en) Monoclonal antibodies to growth and differentiation factor 15 (gdf-15)
RU2430112C2 (ru) Композиции и способы диагностики и лечения опухоли
CN109369808B (zh) 用于治疗ror1癌症并抑制转移的抗体和疫苗
EP3122775B1 (en) Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
KR101838310B1 (ko) 암의 치료를 위한 인간화 항-cxcr4 항체들
KR20120051734A (ko) 항-ｃＭＥＴ 항체 및 암의 검출과 진단을 위한 그의 용도
JP2019506391A (ja) リンパ球における阻害経路の中和
KR20190130506A (ko) 골수유래억제세포 관련 질환의 예방 및 치료 용도
KR102350251B1 (ko) 새로운 igf-1r 항체 및 암의 진단을 위한 그의 용도
KR20250099286A (ko) Eltd1에 대한 단일클론성 항체 및 이의 용도
KR102350259B1 (ko) Igf-1r 항체 및 암의 진단을 위한 그의 용도
TW202302635A (zh) Ｉｌ－３８專一性抗體
HK40005045B (zh) 用於治疗ror1癌症并抑制转移的抗体和疫苗
HK40005045A (en) Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
HK1210950B (en) Monoclonal antibodies to growth and differentiation factor 15 (gdf-15)
HK1231096B (en) Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
HK1231096A1 (en) Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)